waldenstroms.info – A BeiGene initiative


What is waldenstroms.info?

waldenstroms.info is a dedicated resource where Ex-US/Ex-Canada healthcare providers (HCPs) can find up-to-date information on Waldenström’s macroglobulinemia (WM).

WM is a chronic, indolent, low-grade B-cell lymphoma characterized by bone marrow infiltration with lymphoplasmacytic cells and IgM monoclonal gammopathy. Despite an indolent disease course, early diagnosis of WM is essential to treat symptoms and to avoid irreparable organ damage or fatal complications.1,2,3

The aim of waldenstroms.info is to increase awareness and understanding of this rare disease to promote earlier diagnosis and the best possible standards of care for patients.




Waldenstroms Macroglobulinemia
The home of up-to-date medical information on Waldenström’s macroglobulinemia.


What does waldenstroms.info offer?

On waldenstroms.info, HCPs can find educational medical information on WM symptoms1, diagnosis4,5 and treatment options4,5, and explore the latest expert insights into the disease. A dedicated patient support section provides HCPs with a list of patient support groups that may be useful for their patients.



Ongoing studies section

In the ongoing studies section, HCPs can learn more about the recent clinical trials in Waldenström’s macroglobulinemia, and the potential implications of emerging data for novel treatment strategies. The studies selected include phase II or III trials of targeted, chemotherapy-free agents:


waldenstroms.info – The home of up-to-date medical information on Waldenström’s macroglobulinemia.

Why does BeiGene support waldenstroms.info?

At BeiGene we are focused on serving our patients. Through the waldenstroms.info initiative, we aim to raise awareness about this rare disease and improve patient care by disseminating medical education to treating physicians.




  1. Kaseb H, et al.Cancer, Lymphoplasmacytic Lymphoma (Waldenstrom Macroglobulinemia) 2020.
  2. Mazzucchelli M, Frustaci AM, Deodato M, Cairoli R, Tedeschi A.Waldenström macroglobulinemia: An update. Mediterr J Hematol Infect Dis 2018: 10;e2018004.
  3. Gertz MA, Fonseca R, Rajkumar SV.Waldenström’s Macroglobulinemia. The Oncologist 2000: 5(1);63-67.
  4. Kastritis E, Leblond V, Dimopoulos MA, et al.On behalf of the ESMO guidelines committee. Waldenström’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology 2018:29 (Supplement 4);iv41–iv50.
  5. Kumar KS, Callander NS, Baljevic M, et al.NCCN Clinical practical guideline in Oncology (NCCN Guidelines). Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma. September 1, 2020.
  6. Tam CS, Opat S, D’Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood 2020:136(18);2038-2050.
  7. Dimopoulos M, Sanz RG, Lee H, et al.Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. Blood Adv 2020: 4(23);6009–6018.
  8. Dimopoulos MA, Tedeschi A, Trotman J, et al.Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia. N Engl J Med. 2018: 378;2399-2410.
  9. Buske, C, Tedeschi A, Trotman J, et al.Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom’s Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATETM Study. 62nd ASH Annual Meeting Exposition abstract.
  10. Owen, RG, McCarthy, H, Rule, et al.Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haemotology 2020: 7(2);E112-E121.
  11. Sekiguchi N, Rai S, Munakata W, et al.A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström’s Cancer Sci 2020:111(9);3327-3337.
  12. Castillo J, Allan J and Siddiqui T.Multicenter Prospective Phase II Study of Venetoclax in Patients with Previously Treated Waldenstrom Clinical Lymphoma, Myeloma and Leukemia 2019: 19(10);Supp E39-E40.



Licensing of investigational medicines

  • In Europe, Ibrutinib as a single agent is indicated for the treatment of adult patients with WM who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. Ibrutinib in combination with rituximab is indicated for the treatment of adult patients with WM.
  • Zanubrutinib is approved for treatment of adult patients with WM:
    • who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy in the EU and Australia
    • who have received at least one prior therapy in China
  • Acalabrutinib is not licensed worldwide for WM
  • Tirabrutinib is not licensed worldwide for WM
  • Venetoclax is not licensed worldwide for WM.